BioSpace News Archive

Théa Pharma Inc. announced the completion of its previously announced acquisition of seven branded ophthalmic products from Akorn Operating Company LLC.

Altamira Therapeutics Ltd., a company dedicated to developing therapeutics that address important unmet medical needs, announced that its affiliate, Altamira Medica, has received the necessary approvals to initiate a clinical investigation of Bentrio™ in COVID-19 patients.

Dr. Paul Gagne and the research team at Vascular Breakthroughs, LLC, and Vascular Care Connecticut have reached a key clinical development milestone in their participation in the DEXTERITY clinical trials with enrollment of their first patient.

Dr. Robert Shahverdyan, Head of Vascular Access Center at Asklepios Klinik Barmbek of Hamburg, Germany, in partnership with Dr. Dirk Hentschel, President-Elect of VASA and Interventional Nephrologist at Brigham and Women’s Hospital of Boston, MA, have recently published a retrospective analysis of 150 consecutive radiocephalic (forearm) fistula VasQ™ External Support procedures at Seminars in Dialysis.

Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to meet the needs of cancer patients, announced that Prof. Wayne Marasco, M.D., Ph.D. has joined its Scientific Advisory Board.

Cellevolve Bio (“the Company” or “Cellevolve”), and Seattle Children’s Therapeutics, today announced a collaboration aimed at developing and commercializing a suite of novel multiplex CARs for the treatment of pediatric CNS malignancies.

In establishing the business, BMS completed a non-brokered private placement for proceeds of $500,000 on March 7, 2022.

In 2021 the Company initiated a series of cancer screening studies aimed at uncovering therapeutic opportunities for cepharanthine when used alone or in combination with standard of care (SoC) chemotherapy drugs.

Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction.

Increasing demand for genetic testing in fetuses due to growing incidences of genetic disorders, integration of advanced bioinformatics to provide accurate information about the baby, and rising need for non-invasive testing methods are some key factors expected to drive Non-Invasive Prenatal Testing market growth.